NCT01348503终止1 期
A Phase I Open-label Dose-escalation Study With Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Number of Participants with Dose Limiting Toxicities as a Measure of Safety of the combination of lenalidomide and sorafenib.
研究概览
简要总结
The purpose of this study is to evaluate the combination of Revlimid® (lenalidomide) and Nexavar® (sorafenib) for the treatment of hepatocellular carcinoma that can't be cured with surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical or pathological diagnosis of unresectable hepatocellular carcinoma (HCC) based on radiologic criteria, elevated alpha fetoprotein and/or tissue biopsy
- •All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 28 days prior to treatment in this study
- •Child-Pugh Liver Function Class A/B9
- •Eastern Cooperative Oncology Group (ECOG) performance status of </= 2 at study entry
- •Laboratory test results within protocol-specific ranges
- •Disease free of prior malignancies for >/= 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.
- •All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist® (Revlimid is only available under a restricted distribution program called "RevAssist.")
- •Females of childbearing potential must have two negative pregnancy tests before starting lenalidomide and must agree to use two methods of birth control and submit to pregnancy tests throughout the study.
- •Able to take aspirin daily as prophylactic anticoagulation
- •Age >18 years at the time of signing the informed consent form
- •Life expectancy of at least 30 days
排除标准
- •No serious medical condition, laboratory abnormality, or psychiatric illness (including no evidence of hepatic encephalopathy) that would prevent the subject from signing the informed consent form
- •No pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide)
- •No patients who have undergone surgical resection or received chemotherapy, percutaneous ethanol injection, radiation therapy or chemoembolization within 30 days prior to commencement of the study
- •No condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- •No use of any other experimental drug or therapy within 28 days of baseline
- •No known hypersensitivity to thalidomide
- •Patients who developed erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs will be excluded
- •No prior use of lenalidomide
- •No concurrent use of other anti-cancer agents or treatments
- •No known positivity for HIV or infectious hepatitis, type B-8/9 or C
- •No active infection not controlled effectively with antimicrobial or antiviral therapy
研究组 & 干预措施
Open Label, Single Arm
Experimental
Dose escalation of lenalidomide in combination with sorafenib at standard doses in patients with advanced, unresectable hepatocellular carcinoma.
干预措施: Lenalidomide (Drug)
Open Label, Single Arm
Experimental
Dose escalation of lenalidomide in combination with sorafenib at standard doses in patients with advanced, unresectable hepatocellular carcinoma.
干预措施: Sorafenib (Drug)
结局指标
主要结局
Number of Participants with Dose Limiting Toxicities as a Measure of Safety of the combination of lenalidomide and sorafenib.
时间窗: 2 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLLSmall Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT00543114Dana-Farber Cancer Institute9
已完成
2 期
Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular LymphomaFollicular LymphomaNCT01393756The Lymphoma Academic Research Organisation80
已完成
3 期
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular LymphomaFollicular LymphomaNCT01476787Celgene1,030
终止
2 期
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple MyelomaMultiple MyelomaNCT00843310NYU Langone Health8
终止
1 期
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma Grade III (FL III°)Mantle Cell Lymphoma (MCL), Blastoid VariantBurkitt Lymphoma (BL)Aggressive Marginal Zone Lymphoma (MZL)NCT02983097Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH34